Skip to main content

Table 3 Characteristics that are statistically different between patients with high serum TNC and high serum periostin levels and others

From: Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E

 

High TNC > 37.16

Low TNC < 37.16

High TNC > 37.16

Low TNC < 37.16

P value for multigroup analysis†

Groups B, C and D

P value between groups A and E‡

High periostin > 95

High periostin > 95

Low periostin < 95

Low periostin < 95

A (n = 20)

B (n = 21)

C (n = 32)

D (n = 53)

E (n = 106)

GINA step 4 + 5, n (%)

17 (85.0)

7 (33.3)

25 (78.1)

32 (60.4)

0.001*

64 (60.4)

0.042*

AERD, n (%)

6 (30.0)

0 (0.0)

1 (3.1)

5 (9.4)

0.004*

6 (5.7)

0.004*

Daily dose of ICS (FP equivalent dose, µg)

735.00 ± 346.83

392.86 ± 346.51

629.69 ± 349.39

575.47 ± 407.10

0.021*

555.66 ± 384.91

0.045*

FeNO (ppb)

65.30 ± 46.36

65.87 ± 34.04

54.51 ± 52.86

47.21 ± 39.25

0.033*

53.11 ± 43.12

0.208

Peripheral neutrophils (cells/μL)

4588.06 ± 1452.31

3496.31 ± 1052.69

4216.49 ± 1600.66

3900.12 ± 1535.39

0.037*

3915.63 ± 1482.52

0.032*

Peripheral eosinophils (cells/μL)

423.03 ± 315.58

354.16 ± 243.56

223.62 ± 224.07

191.55 ± 159.50

0.001*

233.44 ± 206.28

0.005*

Serum periostin (ng/mL)

138.65 ± 37.94

114.33 ± 17.18

67.81 ± 15.66

69.81 ± 14.82

< 0.001*

78.03 ± 23.81

< 0.001*

Serum TNC (ng/mL)

57.93 ± 18.62

25.42 ± 8.56

62.44 ± 29.95

24.25 ± 7.94

< 0.001*

36.01 ± 24.80

< 0.001*

FVC (L)

2.72 ± 0.93

3.17 ± 0.86

3.38 ± 0.89

3.34 ± 0.98

0.063

3.32 ± 0.93

0.010*

%FVC (predicted, %)

96.10 ± 9.38

103.77 ± 16.30

102.95 ± 16.61

105.47 ± 17.57

0.118

104.37 ± 16.92

0.019*

FEV1 (L)

1.99 ± 0.80

2.28 ± 0.59

2.47 ± 0.83

2.52 ± 0.80

0.062

2.46 ± 0.77

0.014*

PEF (L/s)

6.39 ± 2.00

6.92 ± 1.42

7.46 ± 2.35

7.54 ± 2.05

0.142

7.39 ± 2.04

0.045*

MMF (L)

1.51 ± 1.01

1.64 ± 0.69

1.99 ± 1.07

2.21 ± 1.14

NS

2.03 ± 1.06

0.045*

%MMF (predicted, %)

48.14 ± 24.36

54.37 ± 20.36

56.33 ± 26.21

66.39 ± 30.28

NS

60.97 ± 27.67

0.042*

  1. Data are presented as the mean ± standard deviation unless otherwise indicated
  2. ACT asthma control test, AERD aspirin-exacerbated respiratory disease, BMI body mass index, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GINA Global Initiative for Asthma, ICS inhaled corticosteroid, IgE immunoglobulin E, MMF mid-maximal flow rate, OCS oral corticosteroids, PEF peak expiratory flow, PSL prednisolone, Th2 T-helper cell type 2, TNC tenascin-C, NS not significant
  3. *P < 0.05
  4. †Multigroup analysis performed by Chi square test, One-way ANOVA and Kruskal–Wallis test as appropriate
  5. ‡Comparisons performed by Student’s t test, the Mann–Whitney U test, and Fisher’s exact test as appropriate
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us